3 ASX healthcare shares outperforming on quarterly updates

These stocks are charging ahead on an otherwise lacklustre trading day.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%.

But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day.

Here's why.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

ASX healthcare share Paradigm Biopharmaceuticals is up 5.88% to 27 cents per share at the time of writing. This follows the release of the company's quarterly activities report. Paradigm revealed a cash balance of $26.2 million as of 31 March, down from $33.5 million on 31 December. Paradigm spent $13.1 million on research and development, down from $27.06 million in the previous quarter. Net cash outflow for the quarter was $6.8 million, which was less than the $8 million to $11 million guidance. The company revised its cash outflow guidance for the June quarter to a range of $7 million to $10 million.

Paradigm shares are down 39% in the year to date. Over the past 12 months, the ASX healthcare share has fallen 72%.

Imugene Ltd (ASX: IMU)

The Imugene share price is up 2.44% to 8.4 cents per share at the time of writing. The clinical-stage immuno‐oncology company has also released its quarterly activities report today. The highlights include a cash or equivalents balance of $114.1 million. Net cash used in operating activities amounted to $25.2 million, with direct research and development costs accounting for 49% of costs.

This ASX healthcare share is down 23% in the year to date. Over the past 12 months, the Imugene share price has fallen 35%.

Aroa Biosurgery Ltd (ASX: ARX)

ASX healthcare share Aroa Biosurgery is currently up 3.09% to 50 cents per share. In its quarterly update today, Aroa reported strong cash receipts from customers of NZ$18 million, reflecting a continued increase in Myriad and OviTex / OviTex PRS sales. There were positive net cash inflows from operations of NZ$300,000, exceeding Q4 breakeven expectations. Net cash outflows from investing activities were down to NZ$700,000, reflecting continued planned investment into additional manufacturing plants and equipment. Completion is expected by Q3 FY25. Aroa booked a 71% reduction in quarterly cash burn to about NZ$1 million, ending the year with a strong closing cash balance of NZ$29.5 million.

Aroa shares are down 39% in the year to date. Over the past 12 months, the ASX healthcare share has dropped 53%.

ASX healthcare shares vs. ASX 200

ASX healthcare stocks have fallen 0.5% in the year to date and are down 5.1% over the past 12 months.

By comparison, the ASX 200 has risen 0.35% in 2023 so far and is up 4.4% over the past year.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »